Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)

Authors:
  • EFE. Felip
    E. Felip
  • SOS. Orlov
    S. Orlov
  • KPK. Park
    K. Park
  • CYC.-J. Yu
    C.-J. Yu
  • CTC.-M. Tsai
    C.-M. Tsai
  • MNM. Nishio
    M. Nishio
  • MDM.C. Dols
    M.C. Dols
  • MMM. McKeage
    M. McKeage
  • WSW.-C. Su
    W.-C. Su
  • GSG. Scagliotti
    G. Scagliotti
  • DSD.R. Spigel
    D.R. Spigel

Abstract
Background: In the pivotal ASCEND-1 study, ceritinib showed whole body efficacy in ALKi-naïve pts with ALK+ NSCLC (including those with baseline BM), most of whom had received multiple prior therapies; median progression-free survival (mPFS) was 18.4 mo. The ASCEND-3 single-arm, open-label multicentre study evaluated the efficacy and safety of ceritinib in previously treated ALKi-naïve pts with ALK+ NSCLC (NCT01685138).